When both the clinician and the patient agree that intervention is warranted, treatment options include the administration of anti-VEGF agents to promote the regression of neovascularization during the reabsorption of the hemorrhage, or the surgical approach of vitrectomy combined with PRP to remove the vitreous hemorrhage and associated neovascular membranes [3]. The gene discussed is VEGFA; the disease is hemorrhage.